

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicants:** Nicholas K. Hayward, et al.**Examiner:** Unassigned**Serial No.:** Unassigned**Art Unit:** Unassigned**Filing Date:** Herewith**Docket:** 10441B**For:** A NOVEL GROWTH FACTOR AND A
GENETIC SEQUENCE ENCODING SAME**Date:** July 17, 2001Assistant Commissioner for Patents
Washington, DC 20231**PRELIMINARY AMENDMENT**

Sir:

Prior to examination, please amend the above-identified patent application as follows:

IN THE SPECIFICATION:

Page 1, before line 5, please insert the following:


--CROSS REFERENCE TO RELATED APPLICATION

The present application is a divisional of application Serial Number
08/765,588, filed February 22, 1996.--

CERTIFICATE OF MAILING BY "EXPRESS MAIL"**"Express Mail" mailing label number:** EL895322243US**Date of Deposit:** July 17, 2001

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Dated: July 17, 2001


Janet Grossman

IN THE CLAIMS:

Please cancel Claims 1-42 before calculating the filing fee of this divisional application.

Please add the following new Claims 43-58:

43. An isolated polypeptide comprising SEQ ID NO:4 or having at least about 90% similarity to SEQ ID NO:4.

44. An isolated polypeptide comprising SEQ ID NO:8 or having at least about 90% similarity to SEQ ID NO:8.

45. An isolated polypeptide comprising SEQ ID NO:10 or having at least about 90% similarity to SEQ ID NO:10.

46. A recombinant polypeptide comprising SEQ ID NO:4 or having at least about 90% similarity to SEQ ID NO:4.

47. A recombinant polypeptide comprising SEQ ID NO:8 or having at least about 90% similarity to SEQ ID NO:8.

48. A recombinant polypeptide comprising SEQ ID NO:10 or having at least about 90% similarity to SEQ ID NO:10.

49. A pharmaceutical composition comprising an isolated polypeptide according to any one of Claims 43, 44 or 45 and a pharmaceutically acceptable carrier or diluent.

50. An isolated polypeptide consisting of an amino acid sequence of SEQ ID NO:4 or having at least about 90% similarity to SEQ ID NO:4.

51. An isolated polypeptide consisting of an amino acid sequence of SEQ ID NO:8 or having at least about 90% similarity to SEQ ID NO:8.

52. An isolated polypeptide consisting of an amino acid sequence of SEQ ID NO:10 or having at least about 90% similarity to SEQ ID NO:10.

53. A recombinant polypeptide consisting of an amino acid sequence of SEQ ID NO:4 or having at least about 90% similarity to SEQ ID NO:4.

54. A recombinant polypeptide consisting of an amino acid sequence of SEQ ID NO:8 or having at least about 90% similarity to SEQ ID NO:8.

55. A recombinant polypeptide consisting of an amino acid sequence of SEQ ID NO:10 or having at least about 90% similarity to SEQ ID NO:10.

56. An isolated antibody to the polypeptide comprising an amino acid sequence of SEQ ID NO:4.

57. An isolated antibody to the polypeptide comprising an amino acid sequence of SEQ ID NO:8.

58. An isolated antibody to the polypeptide comprising an amino acid of SEQ ID NO:10.

REMARKS

Applicants have cancelled Claims 1-42 without prejudice. Claims 43-58 have been added. Support for Claims 43-55 is found throughout the specification and particularly at Page 3, line 12 – Page 4, line 5, Page 6, lines 20-25, Page 14, lines 24-32 and Page 16, lines 14-20, for example. Support for Claims 56-58 is found at Page 9, lines 7-9, for example. No new matter has been added.

Accordingly, the present application is in condition for allowance which action is earnestly solicited.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB:bb